cough variant asthma
Conditions
Interventions
Treatment group:Jingfang Keli,Boiled water infusion, one bag at a time, three times a day, with a course of seven days
Sponsors
ZhuJiang Hospital of Southern Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1.Patients who meet the diagnostic criteria for cough variant asthma 2.Diagnosis of cough in traditional Chinese medicine and differentiation of symptoms as wind cold attacking lung syndrome or wind cold attacking lung with phlegm dampness syndrome 3.Age range between 18 and 80 years old (including 18 and 80 years old), regardless of gender 4.Able to engage in language or written communication, agree to participate in this study and sign a written informed consent form
Exclusion criteria
Exclusion criteria: 1. When screening for chronic lung disease, including moderate to severe COPD (chronic obstructive pulmonary disease), AECOPD (acute exacerbation of chronic obstructive pulmonary disease), interstitial lung disease, cystic fibrosis, and pulmonary arterial hypertension; Respiratory infections caused by underlying diseases such as congenital respiratory malformations, congenital heart disease, gastroesophageal reflux disease, and pulmonary dysplasia, with clear evidence of bacterial infection. 2. Currently suffering from diseases that seriously affect the immune system (such as human immunodeficiency virus (HIV) infection, or hematological disorders), or having a history of splenectomy, organ transplantation, etc. 3. Individuals who are known to be allergic to the ingredients of Jingfang granules. 4. According to the judgment of the researcher, patients with the following serious chronic systemic diseases affect the efficacy evaluation and disease outcome: ? poorly controlled diabetes (under the condition of standardized hypoglycemic treatment, the blood glucose at random within 7 days before enrollment is greater than 11.1 mmol/L); ? Poorly controlled hypertension (with standardized use of antihypertensive drugs, systolic blood pressure>160mmHg or diastolic blood pressure = 90mmHg); ? Malignant tumors, severe cardiovascular and cerebrovascular diseases (such as heart failure, cardiomyopathy, dementia, etc.); ? Chronic kidney disease (including stages 3-5 of chronic kidney disease) or blood creatinine (Scr)>1.2 times the upper normal limit or creatinine clearance rate (Ccr) = 50mL/min; Chronic liver disease (such as liver fibrosis, cirrhosis, or serum aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) = 3 times the upper limit of normal values or total bilirubin exceeding the upper limit of normal values). 5. Those who have neurological or psychiatric disorders and are unable or unwilling to cooperate. 6. Heavy smokers (>60 packs/year, each pack=20 cigarettes); Have a history of chronic alcoholism, drug abuse, or any factors that affect study compliance. Pregnant, lactating women, or patients with family planning within the past 6 months. 8. Screening for investigational drugs with a half-life of 5 months prior to screening or participating in other clinical trials (whichever is longer), or currently participating in other clinical trials. According to the researcher's judgment, other lesions or situations that may reduce the likelihood of enrollment or complicate enrollment, such as pregnancy, frequent changes in work environment, unstable living environment, etc., can easily lead to loss of follow-up. 10. Other situations where the researcher deems it inappropriate to participate in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Cough symptom score; | — |
Secondary
| Measure | Time frame |
|---|---|
| Traditional Chinese Medicine Syndrome Points;Hypersensitivity C-reactive protein;Vital signs; | — |
Countries
People's Republic of China
Contacts
Public ContactDongHui Liang
ZhuJiang Hospital of Southern Medical University
Outcome results
None listed